POLATUZUMAB VEDOTIN

Brand name:

• Polivy®

Pharmaceutical company:

Roche Products Pty Ltd

Condition/indication:
(therapeutic use)

• Diffuse large B-cell lymphoma (DLBCL)

PBAC Submission type:

New listing (Major)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents - November 2019

Related medicines:

--

Submission received for:

November 2019 PBAC meeting

Opportunity for consumer comment:

Open 28/08/2019 and close 09/10/2019 (see PBS Website)

PBAC meeting:

Held on 06/11/2019

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---